

## Review article

## Role of microbes in the pathogenesis of neuropsychiatric disorders

Aranyak Goswami, Frank R. Wendt, Gita A. Pathak, Daniel S. Tylee, Flavio De Angelis, Antonella De Lillo, Renato Polimanti<sup>\*</sup>

Department of Psychiatry, Yale School of Medicine and VA CT Healthcare Center, West Haven, CT 06516, USA

## ARTICLE INFO

## Keywords:

Microbiome  
Gut-brain axis  
Inflammation  
Neuropsychiatric disorders  
Dysbiosis  
Probiotics

## ABSTRACT

Microbes inhabit different anatomical sites of the human body including oral cavity, gut, and skin. A growing literature highlights how microbiome variation is associated with human health and disease. There is strong evidence of bidirectional communication between gut and brain mediated by neurotransmitters and microbial metabolites. Here, we review the potential involvement of microbes residing in the gut and in other body sites in the pathogenesis of eight neuropsychiatric disorders, discussing findings from animal and human studies. The data reported provide a comprehensive overview of the current state of the microbiome research in neuropsychiatry, including hypotheses about the mechanisms underlying the associations reported and the translational potential of probiotics and prebiotics.

## 1. Introduction

Microbes reside in the human body and not all of them are necessarily harmful. Their presence/absence and balance/imbalance are associated with health and disease. Some microbes are beneficial and their diversity across human body sites contributes to the overall health status of an individual (Lloyd-Price et al., 2016; Gevers et al., 2012). Fluctuations in the relative diversity and composition of the microbiome across the human body are hypothesized to affect the risk of several diseases, including inflammatory bowel disease (IBD) (Glassner et al., 2020), cancer (Bhatt et al., 2017), and immunological disorders (Belkaid and Hand, 2014).

There is considerable literature supporting the association between human microbiome variation and mental health, also including several review articles focused on specific disorders or specific mental health domains, such as depression (Marx et al., 2021; Bastiaanssen et al., 2020; Cruz-Pereira et al., 2020), mood disorders (Margolis et al., 2021; Cruz-Pereira and Cryan, 2020), neurodegenerative disorders (Cryan et al., 2020), and neurodevelopment (Cowan et al., 2020). However, to our knowledge, a review presenting the current state of microbiome research across multiple neuropsychiatric disorders and different body sites is missing. The current article aims to provide a compendium of the current state of human microbiome research across the neuropsychiatric spectrum to help investigators with different expertise to understand the evidence available to date. We include an initial overview of three

microbiome domains (gut, mouth, and skin; Fig. 1) and then review findings specifically related to eight neuropsychiatric disorders (Alzheimer's disease, attention deficit hyperactivity disorder, anorexia nervosa, autism spectrum disorder, bipolar disorder, major depressive disorder, schizophrenia, and substance use disorders; Table 1). Due to size constraints, we decided to focus on those psychiatric disorders that were investigated by numerous studies or that were not reviewed previously.

The studies reviewed were conducted using a wide range of different methods and designs. For example, diversity metrics include several measures of alpha diversity (e.g., the Shannon index assumes the observed abundances reflect random sampling of the microbiome and thus is maximized when abundances increase evenly across all taxonomic units; the Simpson index gives more weight to highly abundant taxonomic groups and is less influenced by very low abundance organisms; the Chao1 index uses a Poisson distribution to estimate the number of taxa in a sample by extrapolating the number of rare organisms that may have been missed due to under-sampling; rarefaction assesses species richness through construction of rarefaction curves). Beta diversity reflects a comparison of abundances between two microbiome samples (e.g., Jaccard distance measures similarity in the presence or absence of taxonomic groups without regard to abundance; Bray-Curtis dissimilarity measures the differences in abundances of each taxonomic units; Unweighted UniFrac is the distance between two samples by calculating the fraction of the branch length in a

<sup>\*</sup> Corresponding author at: Yale University School of Medicine, Department of Psychiatry, VA CT 116A2, 950 Campbell Avenue, West Haven, CT 06516, USA.  
E-mail address: [renato.polimanti@yale.edu](mailto:renato.polimanti@yale.edu) (R. Polimanti).

phylogenetic tree that leads to descendants) (Ashton et al., 2016). Because analytic variability undermines comparison between studies and contributes to the lack of reproducibility among microbiome studies, investigators have highlighted the need for establishing standards for microbiome analysis and interpretation (Morton et al., 2019; Sczyrba et al., 2017). Due to the difficulty of comparing results that used different statistics, we decide to compare the finding of the studies reviewed relying on the interpretation made by the authors.

## 2. Gut-brain axis

The gut microbiome is a reservoir of many microorganisms such as *Firmicutes*, *Bacteroides*, *Prevotella*, and *Bifidobacterium* associated with the healthy physical and mental state of an individual. (Lozupone et al., 2012). Gut dysbiosis (i.e., altered abundances of gut microbial communities) has been hypothesized to be involved in gastrointestinal disease (Lozupone et al., 2012; Cummings et al., 2003), cardiovascular illnesses (Tang and Hazen, 2014), metabolic disorders (Blandino et al., 2016) and autoimmune diseases (Blandino et al., 2016; Maeda and Takeda, 2017). With respect to neuropsychiatric disorders, the gut-brain axis (GBA) represents the link between the central and the enteric nervous system, linking emotional and cognitive centers of the brain with peripheral intestinal functions. The association between microbiota and GBA appears to be bidirectional with signaling from gut-microbiota to brain and from brain to gut-microbiota mediated neural, endocrine, immune, and humoral mechanisms (Carabotti et al., 2015). The impact of gut microbes on human health also includes potential associations with increased vulnerability to psychiatric disorders. A well-known study on using a germ-free mouse model emphasized an altered hormonal response to stress, suggesting that microbiota influences the neuroendocrine hypothalamic–pituitary–adrenal (HPA) axis (Sudo et al., 2004). In additional mouse experiments, the lack of normal gut microbiota influences behaviors (e.g., motor activity) and brain transcriptomic profile involved in motor control and behavioral regulations (Heijtz et al., 2011). Another study testing the administration of a mixture of nonabsorbable antimicrobials for 7 days to pathogen-free mice transiently altered the gut microbial composition and was associated with heightened exploratory behavior and hippocampal Brain-Derived Neurotrophic Factor (BDNF) expression (Maqsood and Stone, 2016; Bercik et al., 2011). These changes were independent of other inflammatory activities and alterations at the level of gastrointestinal neurotransmitters. Accordingly, the intestinal microbiota was hypothesized to influence brain chemistry and behaviors independently of the autonomic nervous system and gut inflammation (Bercik et al., 2011).

The gut epithelium plays a key role in the GBA regulation because it

is the primary target for changes induced by dietary, microbial, and inflammatory components. Enterochromaffin (EC) cells function as chemo- and mechanosensory neuroendocrine cells that release serotonin in order to modulate other gastrointestinal neurons, in order to effect peristalsis and mucus secretion. Serotonin released from EC cells in the mouse colon has been attributed to neuroinflammation (Del Angel-Meza et al., 2011; Bellono et al., 2017). There is evidence of sex-differences in this hormonal response to microbiome perturbations. Female germ-free mice showed greater serotonin concentrations and elevated plasma levels of tryptophan (i.e., the serotonin precursor) than conventionally colonized control animals (Clarke et al., 2013). In mouse models of stroke and multiple sclerosis, the perturbation of gut microbiota appears to interfere with communicative and sensorimotor behaviors via immunomodulation (Hsiao et al., 2013).

The gut consists of a high concentration of immune cells, providing an additional layer of defense from pathogens. Production of pro- and anti-inflammatory cytokines is influenced by gut microbiota which can lead to brain dysfunction through the circulatory system (Long-Smith et al., 2020). Inflammation caused by cytokines can result in the release of corticosteroids accelerating stress-induced anxiety and depression (Maydych, 2019). Gut microbiota regulates metabolism of neuroactive compounds (e.g., short-chain fatty acids, indoles, bile acids, choline metabolites, lactate) and their release of these neuroactive compounds can promote additional neuroinflammation (De Vadder et al., 2014; Caspani et al., 2019).

Microbes residing in the gut often metabolize tryptophan, the serotonin precursor, along with a host of other neurotransmitters and neuromodulators (O'Mahony et al., 2015). These compounds permeate the gut wall that is innervated by the enteric nervous system (ENS) (Dinan et al., 2018; Rea et al., 2016). This interaction can trigger bidirectional gut-brain communication resulting in inflammation of the gut and brain epithelia and production of stress peptides resulting in anxiety-driven behaviors (Carabotti et al., 2015). Gut-brain module analysis based on human fecal metagenomes identified microbial production of 3,4-dihydroxyphenylacetic acid (a dopamine metabolite), which correlated positively with self-reported quality of life; this study also indicated the role of microbial  $\gamma$ -aminobutyric acid production in psychopathology (Caspani et al., 2019; Valles-Colomer et al., 2019). Among the pathogenic processes involved in the disruption of gut-brain axis equilibrium, inflammation plays a key role in altering the microbiome homeostasis in response to specific pathogens (Hill et al., 2014), immune activation (Zevin et al., 2016), and antibiotic supplementation (Grazul et al., 2016). This altered microbial environment due to gut infection can be restored via beneficial microbes called probiotics (Petschow et al., 2013). Although this field is still in infancy, it has great potential for the




Fig. 1. Microbiome across different anatomical sites and associated psychiatric disorders.

**Table 1**

Microorganisms, anatomical sites, and associated psychiatric disorders.

Microorganism	Type	Anatomical sites	Psychiatric Disorders
<i>Lactobacillus fermentum</i>	Commensals	Gut	AD
<i>Lactobacillus acidophilus</i>			AD, ASD
<i>Lactobacilli</i>			
<i>Roseburia inulinivorans</i>			AN
<i>Roseburia</i>			
<i>Methanobrevibacter smithii</i>			
<i>Ruminococcus</i>			AN, ASD
<i>B. bifidum</i>			ASD
<i>Bifidobacterium</i>			
<i>Collinsella stercosis</i>			
<i>Lactobacillus bulgaricus</i>			
<i>Lactobacillus fermentum</i>			
<i>Lactobacillus plantarum</i> WCFS			
<i>Veillonella</i>			
<i>Bifidobacterium adolescentis</i>			
<i>Prevotella</i>			
<i>Akkermansia</i>			BD
<i>Faecalibacterium</i>			
<i>Flavonifractor</i>			
<i>Lachnospiraceae</i>			
<i>Butyrivibrio</i>			MDD
<i>Coprococcus</i>			
<i>Dorea</i>			
<i>Pseudobutyrvibrio</i>			
<i>Lactobacillus phage phiadh</i>			SZ
<i>Leptotrichia</i>	Pathogens	Gut, Oral Cavity	SUD
<i>Peptostreptococcus</i>		Gut, Oral cavity, Skin, Vagina	
<i>Propionibacterium acnes</i>		Gut, Skin	AD
<i>Corynebacterium</i>		Skin	ASD, AD, MDD
<i>Weeksellaceae</i>			SZ
<i>Enterobacteria</i>		Gut	AD, ASD
<i>Clostridium difficile</i>			
<i>Enterobacter</i>			AD, MDD, ASD
<i>Clostridium</i>			AN, ASD
<i>Clostridium bolteae</i>			ASD
<i>Klebsiella</i>			
<i>Clostridium coccoides</i>			
<i>Clostridium histolyticum</i>			
<i>Escherichia coli</i>			
<i>Alistipes</i>			MDD
<i>Measles morbillivirus</i>			SZ
<i>Saccharomyces cerevisiae</i>		Gut, Skin	SZ
<i>Streptococcus</i>		Oral cavity	ADHD, ASD, BD, MDD

**Table 1 (continued)**

Microorganism	Type	Anatomical sites	Psychiatric Disorders
<i>Neisseria</i>		Oral cavity, Skin, Vagina	ASD
<i>Megasphaera</i>			ASD, SZ
<i>Moraxella</i>			ASD, SZ, BD
<i>Capnocytophaga</i>			SUD
<i>Rothia</i>			
<i>Capnocytophaga</i>			SZ
<i>Haemophilus</i>			
<i>Herpes simplex virus</i>			
<i>Cytomegalovirus</i>		Oral cavity, Urinary tract	
<i>Epstein-Barr virus</i>		Oral cavity, Vagina	
<i>Rubella</i>		Urinary tract	
<i>Candida albicans</i>		Vagina	

**Abbreviations-** AD: Alzheimer's disease, ADHD: Attention Deficit Hyperactivity Disorder, AN: Anorexia Nervosa, ASD: Autism Spectrum Disorder, BD: Bipolar Disorder, MDD: Major Depressive Disorder, Schizophrenia: SZ, SUD- Substance Use Disorder.

development of therapeutic applications (Kashyap et al., 2017; Zmora et al., 2016; Kuntz and Gilbert, 2017).

### 3. Oral microbiome

The human oral cavity is a complex environment presenting a variety of habitats hosting different kinds of microorganisms (Dewhirst et al., 2010). Highly prevalent microorganisms in the oral cavity include *Staphylococcus* (Schulze-Schweifing et al., 2014; Wade, 2013) and *Streptococcus* (Butler et al., 2017). Data regarding different oral microbiome species are available from the Human Oral Microbiome Database (HOMD) (Chen et al., 2010). Compared with the gut microbiome, few studies examined the oral microbiome in the context of neuropsychiatric disorders (Logan et al., 2016). The microbiome in the oral cavity has been associated with systemic inflammation linked to altered cognitive functioning (Yolken et al., 2020). This may be due to indirect factors such as diet, lifestyle, and oral hygiene, but the fact that the association was related to a specific species (i.e., *Neisseria subflava*) suggests the possibility of a direct link. Unfortunately, to date the underlying mechanisms are still unclear. Due to many confounders that can affect the human variation of oral microbiome composition, most of the current studies should be considered as preliminary evidence that needs confirmation in a larger and more carefully characterized samples (Kong et al., 2019).

### 4. Skin microbiome

Skin serves as a barrier preventing the invasion of external pathogens and also acts as the primary habitat for the commensal microbiota (Grice and Segre, 2011). Sebaceous sites in the skin are reservoirs of specific bacteria like lipophilic *Propionibacterium*; *Staphylococcus*, and *Corynebacterium* species (Scharschmidt and Fischbach, 2013). Skin microbiome diversity is generally conserved at the community level and despite external perturbations like diet, antimicrobial therapy, and long-term environmental interactions, it is considered stable over time in healthy individuals (Oh et al., 2016). Alteration of skin microbiota is observed when individuals are affected by wounds, lesions, and/or dermatological disorders. Very few studies investigated the impact of skin microbiome dysbiosis with respect to psychiatric disorders. However, some of them hypothesized the presence of a gut-brain-skin axis related to

immune response and inflammatory processes linking these organs (Hadian et al., 2020; Salem et al., 2018; Arck et al., 2010). Bidirectional communication between skin and gut microbiota has been reported in the context of immune-related disorders (Lloyd-Price et al., 2016; Lee et al., 2018; Prieto and Cotman, 2017). For example, variation in gut microbiome in patients with skin lacerations has been reported to alter the skin microbiota (Salem et al., 2018; Gilbert et al., 2018; O'Neill et al., 2016). Persistent changes in both gut and skin microbiome can lead to neuro-modulatory effects associated with decreased cognitive function via inflammatory cytokines (i.e., TNF- $\alpha$ , IL-1 $\beta$ , IL-6, IFN- $\alpha$ ) (Hadian et al., 2020). These factors have been associated with gut inflammation, increasing the permeation of the gut-brain barrier resulting in the release of neurotransmitters (Clapp et al., 2017; Pearson-Leary et al., 2020; Liu, 2017). In patients with psoriasis, alterations in the skin and intestinal microbiome play a role in the pathogenesis of psoriasis, where inflammatory and immune mechanisms are associated with the dysregulation of the hypothalamic–pituitary–adrenal axis (Wang et al., 2021; Chen et al., 2020).

## 5. Alzheimer's disease

Alzheimer's disease (AD) is a leading cause of death worldwide, with an estimated incidence of 1–3% and a prevalence of 10–30% of the population >65 years of age in the United States (Masters et al., 2015; Gaugler et al., 2019). The role of altered gut microbiota and its subsequent impact on the HPA axis has been studied in the context of AD pathophysiology (Kim and Shin, 2018). The leading hypothesis is that the composition of the intestinal microbiome plays a role in the neuro-inflammation of the amyloid plaques deposition (Minter et al., 2016). Indeed, microbiota-mediated inflammation associated with AD appears to act at the level of the blood–brain barrier (BBB) (Kowalski and Mulak, 2019). Some bacteria are capable of directly crossing the BBB, giving rise to infections of the central nervous systems (CNS) (Coureuil et al., 2017). Certain molecules generated by bacteria (e.g., lipopolysaccharide, LPS) potentially stimulate BBB disruption in patients affected by neurodegenerative disorders. (Xiao et al., 2001). Consistent with this, the bacterial metabolite propionate, a short-chain fatty acid (SCFA), appears to protect the BBB from damage via inhibiting oxidative stress thereby maintaining its integrity. (Hoyles et al., 2018). LPS is typically associated with pathogenic strains, while commensal or non-pathogenic flora produce SCFAs. In rats, peritoneal LPS administration resulted in increased levels of inflammatory factors, notably IL-1, IL-6, and TNF- $\alpha$ , in the hippocampus, suggesting a role for the microbiome in the initiation of an innate immune response in AD (Zhu et al., 2014). Zhao and colleagues found immunohistochemical evidence of microbiome-derived LPS within the perinuclear region of human AD brains (Zhao et al., 2017).

The natural biodiversity of the gut microbiome tends to decline with aging, with a relative reduction in commensal species, such as *Bacteroides*, *Bifidobacteria*, and *Lactobacilli*, and a relative increase in opportunists and potentially pathogenic species such as *Enterobacteria*, *C. perfringens*, and *C. difficile* (Nagpal et al., 2018). In the ELDERMET cohort comprised of individuals over 65 years of age, there was a shift in the gut microbiota toward a *Bacteroidetes*-predominated population in older individuals compared to younger participants (Claesson et al., 2011). The variation in microbial composition is also dependent on diet and lifestyle (Nagpal et al., 2020). Diet-induced perturbation in the gut microbiome alters the shikimate metabolic pathway (responsible for the *de novo* synthesis of aromatic compounds in microorganisms (Mir et al., 2015), which was associated with elevated levels of the cytotoxic amine tryptamine and increased symptoms among individuals affected by AD (Paley, 2019). In human brain samples, a large bacterial load of *Firmicutes* species and *P. acnes* was observed in the cerebral cortex of AD patients (Emery et al., 2017).

Ongoing studies are exploring the role of probiotics used in gastrointestinal (GI) diseases for the treatment of AD patients. (Leblhuber

et al., 2018). Certain probiotic formulations displayed neuroprotective effects in a transgenic mouse model of AD, including attenuation of microglial activation, reduction in A $\beta$  load, and preservation of dendritic spine structure and function (Kitazawa et al., 2012; Chunchai et al., 2018). A relatively larger randomized controlled trial (N = 60) revealed that intake of milk supplemented with *Lactobacillus acidophilus*, *Lactobacillus casei*, *Bifidobacterium bifidum*, and *Lactobacillus fermentum* produced significant, albeit small magnitude improvement in Mini-Mental Status Examination scores (widely used to test cognitive function among the elderly (Mitchell, 2009) and improvement on various metabolic measures in AD patients (Akbari et al., 2016). With respect to the oral microbiome, a large scale retrospective case-control study of Alzheimer's disease (AD) including participants from Taiwan's national insurance database (N = 209,112 cases and 836,448 dementia-free controls) found negative associations with the per-person cost of dental care, number of root canals, and number of tooth extractions, and positive associations with the cost of dental imaging and dental emergencies (Lin et al., 2020).

## 6. Attention deficit hyperactivity disorder

Attention-deficit hyperactivity disorder (ADHD) is a heterogeneous neurodevelopmental disorder (Aarts et al., 2017). Diet potentially plays an important role in ADHD-related behavioral processes via its effect on the composition and functioning of the gut microbiome (Szopinska-Tokov et al., 2020). Apart from diet, host-microbe interaction with the gut-brain axis could be directly involved in the development of ADHD (Bull-Larsen and Mohajeri, 2019). The host-microbiome interactions have implicated effects on hormones and neurotransmitter levels thought to be involved in the pathophysiology of ADHD (Wan et al., 2020; Bull-Larsen and Mohajeri, 2019). For instance, GABA production has been associated with different microbial genera including *Bifidobacterium*, *Lactobacillus*, and *Escherichia coli* (Petra et al., 2015). Gut dysbiosis in combination with immune dysfunction caused by constant pathogen exposure could contribute to hyperactive behaviors observed in ADHD affected patients (Ming et al., 2018). A study administering probiotics to ADHD patients showed that early intervention with *Lactobacillus* reduced the risk of ADHD development later in childhood (Kumperscak et al., 2020). ADHD has been associated with abnormalities in the predicted dopamine and noradrenaline synthesis, whose precursors are provided by the gut bacteria (Aarts et al., 2017). ADHD is often found to be associated with gut dysbiosis like enrichment or depletion of certain bacteria like *Bifidobacterium* (Bull-Larsen and Mohajeri, 2019).

## 7. Anorexia nervosa

Anorexia nervosa (AN) is a mental illness characterized primarily by feeding restriction, distorted perceptions of and preoccupation with body weight and shape, and obsessive behaviors related to food (Solomon et al., 2020). Metabolic, immunologic, and weight regulating effects of the microbiome could influence the course and prognosis of the disease. Additionally, the interplay between stress-coping mechanisms and gut microbiome can also have important implications for AN (Kleiman et al., 2015).

AN patients have demonstrated altered diversity of bacterial species within the gut (Seitz et al., 2019; Borgo et al., 2017; Gorwood et al., 2016). In particular, AN patients showed high gut levels of the archaeon *Methanobrevibacter smithii* (Morita et al., 2015). This methane-producing archaeon is associated with food transformation processes in a very low-calorie diet (Armougom et al., 2009). AN patients also have significantly low amounts of total bacteria and obligate anaerobes, e.g. *Clostridium coccoides* group (Morita et al., 2015). The reduced microbial diversity is associated with impaired immune response and reduced capacity to absorb calories from the diet (Ruusunen et al., 2019). Additionally, the genera *Roseburia*, *Ruminococcus*, and *Clostridium* were reduced in line



with the AN depletion of total short-chain fatty acids, butyrate, and propionate (Borgo et al., 2017). Butyrate concentrations inversely correlated with anxiety levels, whereas propionate was positively associated with insulin levels and with an increased presence of *Roseburia inulinivorans* (Borgo et al., 2017).

Due to its therapeutic potential, the interaction of the human microbiome with dietary habits is a rapidly expanding research area in AN (Seitz et al., 2019; Herpertz-Dahlmann et al., 2017). For example, *Roseburia* sp. represents one of the candidates for AN probiotic intervention due to the lower rate of anxiety associated with affected patients (Mack et al., 2018). However, more studies are needed to clarify whether the differences observed are a cause or consequence of the disease. Additionally, it will be important to understand how changes in AN microbiota are affected by the interactions among nutritional supply, nutritional supplements, probiotics (i.e., live bacteria), and prebiotics (i.e., fibers supporting the growth of certain types of bacteria) (Roubalová et al., 2020).

## 8. Autism spectrum disorder

Autism spectrum disorder (ASD) is characterized by impairment in communication, speech, social interaction, and the presence of restricted interests and repetitive or stereotyped behaviors (Matson and Goldin, 2014; Faras et al., 2010). Due to the high prevalence of GI symptoms in ASD-affected individuals, considerable attention has been paid to the gut microbiome (Lasheras et al., 2020). Altered age-related patterns have been associated with ASD-affected individuals, including cognitive impairments, difficulty in speech and motor coordination skills (Schwartz et al., 2017; Dan et al., 2020). A higher representation of *Bacteroidetes*, *Proteobacteria*, and *Firmicutes* has been reported in ASD patients when compared with healthy controls (Coretti et al., 2018). Conversely, ASD showed a reduction of *Bifidobacterium*, *Klebsiella*, *Enterobacter*, *Prevotella*, *Coprococcus*, and *Veillonellaceae* (Horvath et al., 1999; Gondalia et al., 2010; Adams et al., 2011). Earlier studies also suggested that the imbalance in *Bacteroides* and *Firmicutes* gut has been associated with increased autism severity in ASD patients (Tomova et al., 2015). However, this finding was not replicated in certain cohorts, possibly due to different living conditions and eating habits (Zhang et al., 2018). Pyrosequencing of fecal microflora of ASD children showed a higher abundance of *Desulfovibrio* species and *Bacteroides vulgatus* when compared with healthy controls (Finegold et al., 2010). Late-onset autism patients presented a high incidence of *Clostridium* and *Ruminococcus* species with a particular enrichment for *Clostridium* cluster groups I and XI and *Clostridium bolteae* (Liu et al., 2019). The accumulation of neurotoxin-producing bacteria such as *Clostridia* are associated with ASD symptoms (Sivamaruthi et al., 2020). Toxic molecules released by such microbes affect serotonin signaling (Martin et al., 2018), potentially leading to ASD behavioral patterns such as decreased socialization, decreased response to pain, abnormal language, and self-abusive or repetitive behaviors. ASD-affected individuals show altered levels of other potentially toxic compounds produced by several bacteria (e.g., *Bifidobacterium*, *C. difficile*, and *C. histolyticum*) (De Angelis et al., 2015; Ding et al., 2017; Fattorusso et al., 2019; Mohamadkhani, 2018). Among them, increased abundance of urinary and fecal p-cresol (p-cresol) and its conjugated derivative p-cresylsulfate inhibit the enzyme dopamine-beta-hydroxylase (Roman et al., 2018). Additionally, increased *Clostridia*-derived metabolite 3-(3-hydroxyphenyl)-3-hydroxy propionic acid has been detected in ASD-affected individuals, potentially reflecting an altered catecholamine metabolism. Treatment with vancomycin and probiotic *Bifidobacterium* was associated with normalized metabolite levels, decreased constipation, and a reduction in severity of ASD features (Xiong et al., 2016).

Obesity- or diet-induced changes in the offspring gut microbiome have been examined as a potential mediator of the association of maternal obesity with ASD. In rodent models, offspring of mothers who were fed high fat diets showed altered gut microbial composition and

deficits in social behaviors and social reward pathways thought to be relevant to ASDs (Buffington et al., 2016). Fecal inoculation from offspring whose mothers were fed a typical diet (through either cohabitation or fecal transplant) were associated with normalization of social (but not repetitive) behaviors (Buffington et al., 2016).

The gut microbiome metabolizes three classes of short-chain fatty acids (SCFA): propionic acid (PPA), acetic acid, and butyric acid. PPA and SCFA in general are capable of gaining access to the brain and inducing widespread effects on CNS function, including neurotransmitter synthesis and release, calcium influx, intracellular pH maintenance, lipid metabolism, intercellular gating, immune activation, and gene expression (Silva et al., 2020). Perfusion of PPA in rats induced ASD symptoms, supporting the importance of gut-acquired factors (Adams et al., 2011; MacFabe, 2012).

A small open-label clinical trial evaluated the impact of microbiota transfer therapy (MTT; a combination of antibiotics, a bowel cleanse, a stomach-acid suppressant, and fecal microbiota transplant) on gut microbiota composition, GI symptoms, and ASD symptoms in eighteen affected individuals. (Kang et al., 2017). The GI symptom rating scale exhibited an approximately 80% decrease of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain (Kang et al., 2017). Additionally, ASD symptoms improved significantly and remained constant 8 weeks after treatment ended (Kang et al., 2017). The overall bacterial diversity and the abundance of *Bifidobacterium*, *Prevotella*, and *Desulfovibrio* among other taxa increased following MTT, and these changes persisted after treatment stopped (Kang et al., 2017). Parracho and colleagues conducted a double-blind placebo crossover trial in the United Kingdom with 22 children with ASD aged between 3 and 16 years using *Lactobacillus plantarum* WCFS as a probiotic (Parracho et al., 2010). Although no major differences were observed in GI symptoms, a significant increase in *Lactobacilli/Enterococci* and a decrease in the *Clostridium coccoides* were reported in the stool samples of children with ASD when compared with the placebo group.

Another interesting area of ASD research is related to maternal immune activation (MIA) triggered by infectious or infection-like stimuli (Minakova and Warner, 2018). A MIA mouse model showed significant behavioral changes in offspring of potential relevance to ASD (Hsiao et al., 2013). These changes are accompanied by altered gut microbial composition. Oral treatment with human *Bacteroides fragilis* improved the communicative and stereotyped behaviors, as well as altered intestinal permeability associated with microbial composition (Hsiao et al., 2013). The behavioral deficits appeared to be due to the *Clostridium*-associated metabolite 4-ethylphenyl sulfate, a molecule like p-cresol (4-methylphenol) (Hsiao et al., 2013). This is a chemically related metabolite reported being a possible urinary ASD biomarker (Altieri et al., 2011; Gabriele et al., 2014). In another study conducted on ASD-affected children (N = 22), a sugar-free diet and probiotic capsules of *L. acidophilus* were associated with significant improvement in concentration and the ability to follow instructions in affected patients (Fattorusso et al., 2019; Kałużna-Czaplińska and Błaszczyk, 2012). In an additional clinical trial, an oral liquid dose of vancomycin 500 mg/day and followed by probiotic therapy (a mixture of *L. acidophilus*, *L. bulgaricus*, and *B. bifidum*) was associated with an improvement in the cognitive functioning of ASD patients (Sandler et al., 2000).

Beyond the gut environment, microbiome variation in other body sites was also investigated with respect to ASD. For example, certain components of the oral microbiome (abundance of *Rothia*, *Neisseria*, *Moraxella*, *Megasphaera*, and *Gemella*) were associated with autism in children (Forsyth et al., 2020).

## 9. Bipolar disorder

Bipolar disorder (BD) is a chronic mood disorder characterized by periods of abnormally elevated mood in addition to periods of depression, and it is associated with high morbidity (Müller-Oerlinghausen

et al., 2002). Several lines of evidence support the presence of chronic low-grade inflammation among BD-affected persons, with increased plasma cytokines, soluble cytokine receptors, chemokines, acute phase reactants, and T-cell activation. It is unclear the extent to which these findings may be linked with dysbiosis.

In a study comparing the gut microbiota of 115 BD patients and 64 healthy controls (Evans et al., 2017); *Faecalibacterium* levels were decreased in BD patients and abundance was negatively correlated with self-reported symptoms of depression severity. In a separate study, higher microbial variation was observed in BD-affected patients when compared to healthy controls (Guo et al., 2018). Among patients affected by episodes of both mania and depression, the relative increase of *Escherichia coli* and *Bifidobacterium adolescentis* was higher in individuals with manic episodes, while *Stercoris* was higher in individuals with depressive symptoms (Guo et al., 2018; Huang et al., 2019). *Flavonifractor* genus was associated with BD patients (Coello et al., 2019). However, no difference in gut microbiota were observed between unaffected first-degree relatives of BD patients and healthy controls (Coello et al., 2019).

Few studies have examined microbiome interventions in BD. An investigation of 20 euthymic BD-affected individuals, who received a probiotic supplement over 3 months, showed significant improvement in cognition and psychomotor processing speed (Reininghaus et al., 2020). Additionally, one observational study of atypical antipsychotic treatment showed a decreased alpha diversity of gut microbiota in BD female patients and altered abundance of *Lachnospiraceae* and *Akkermansia* in the whole BD group (Flowers et al., 2017).

## 10. Major depressive disorder

Major Depressive disorder (MDD) is the 4th leading cause of disability around the world (Friedrich, 2017). Multiple studies reported associations between microbiome variation and certain biological changes associated with MDD pathogenesis (e.g., neurotrophic factor alterations, neuroanatomical abnormalities, and endocrine and immune system dysfunction) (Naseribafrouei et al., 2014; Jiang et al., 2015). Depression appears to be generally associated with reduced microbial diversity (Cheung et al., 2019). The relative abundance of *Bacteroidetes*; *Proteobacteria*, and *Actinobacteria* phyla were increased in MDD patients whereas that *Firmicutes* abundance was significantly reduced (Jiang et al., 2015). MDD group also showed elevated levels of *Enterobacteriaceae* and *Alistipes* but reduced levels of *Faecalibacterium*, which were also negatively associated with MDD symptoms (Jiang et al., 2015). *Coprococcus*, *Pseudobutyrvibrio*, *Dorea*, and *Clostridium* genera were reported as overrepresented in MDD patients (Galley et al., 2014). Conversely, MDD-depleted bacterial genera include butyrate-producing bacteria like *Dialister*, *Faecalibacterium*, and *Butyrvibrio* (Kelly et al., 2016; Yong et al., 2020). In female MDD patients, it was observed enrichment for *Bacteroidetes*, *proteobacteria*, and *Fusobacteria* and depletion for *Firmicutes* and *Actinobacteria* phyla (Chen et al., 2021). In mouse models, the microbiome profile associated with depressive symptoms has been associated with specific changes in microbial genes and changes in gut metabolism of carbohydrate and amino acids (Zheng et al., 2016; Rogers et al., 2016). The composition of gut microbiota is significantly altered in MDD mice versus healthy GF (germ-free) controls (Cheung et al., 2019; Lach et al., 2018). In mouse models, LPS-administration induces neuroinflammatory changes that effect synaptic and non-synaptic plasticity in basolateral amygdala projection neurons associated with anxiety-related behavior (Zheng et al., 2020). Additionally, the endocrine system communicates bidirectionally with the gut microbiota also via sex hormones, like androgens, estrogens, and others, which can influence MDD-related neuroinflammation (Vemuri et al., 2019; Peirce and Alviña, 2019). Indeed, androgens seem to exhibit anxiolytic properties whereas estrogens have been found to elevate HPA activity (Turner-Cobb et al., 2010). Fluctuations in levels of oxytocin are correlated positively with changes in the gut bacterial taxa whose

abundance was altered in clinical depression (Lach et al., 2018).

Probiotics consumption for extended periods showed beneficial effects on depression-related behaviors, (Wallace and Milev, 2017). One of the other potential therapeutic approaches for depression based on FMT microbial manipulation is the. This therapeutic approach showed positive effects in treating *Clostridium difficile* mediated infection (Moayyedi et al., 2017). GF mice receiving FMT from patients with depression exhibited greater depressive behaviors compared to GF mice receiving FMT from healthy control individuals (Zheng et al., 2016).

## 11. Schizophrenia

Schizophrenia (SCZ) is a chronic psychiatric disorder characterized by a range of symptoms, including delusions, hallucinations, disorganized thoughts, and cognitive deficits (Mattila et al., 2015). The role of microbial diversity in contributing to SCZ has been widely discussed. Imbalance of microbes produced either by pathogen invasion, stress, immune gene activation, or endothelial barrier compromise is associated cognitive impairments and has been hypothesized to occur in individuals with SCZ (Severance and Yolken, 2019). In 1845, Jean-Étienne Esquirol was the first to suggest that infectious diseases are involved in the vulnerability to psychoses (Severance and Yolken, 2019). More recently, SCZ risk has been associated with the exposure to neurotropic viruses (e.g., herpes simplex viruses, cytomegalovirus, Epstein-Barr virus, measles, and rubella) (Khandaker et al., 2014; Alam et al., 2017; Meyer, 2014; Carter, 2011). Nevertheless, viral load in post-mortem brain samples did not show any significant difference between SCZ patients and healthy controls (Murphy et al., 2011). In addition to the established SCZ-associated pathogens, gut microbes could activate cytokine and complement systems, causing neuroinflammation and increasing the risk of psychotic symptoms (Allswede et al., 2016). In one study, maternal complement was elevated in peripheral blood at time of birth in mothers whose children went on to develop severe psychoses (Severance et al., 2014). This complement activation during pregnancy can affect the development of neuronal networks (Severance and Yolken, 2020). Metagenomic studies showed increased fecal abundance of *Lactobacillus* among individuals with first-episode psychosis, as well as diminished response to treatment in those with the strongest evidence of dysbiosis (Schwarz et al., 2018). Additionally, *Lactobacillus* phage *phiadh* showed increased abundance in the oropharyngeal microbiomes of SZ-affected individuals (Schwarz et al., 2018; Yolken et al., 2015).

*Candida albicans* and *Saccharomyces cerevisiae* were observed to be elevated in SCZ patients (Dickerson et al., 2017). In a double-blind, placebo-controlled study, *C. albicans* was elevated in SCZ and was associated with more severe cognitive impairments and psychiatric symptoms (Severance et al., 2017). Probiotic treatment reduced *C. albicans* antibodies over the 14-week study period in males, but not in females.

Another study showed an association of the oropharyngeal microbe *Ascomycota*, being more abundant in SCZ patients than in non-affected individuals (Castro-Nallar et al., 2015). Significant enrichment of lactic acid-producing microbes like *Candida* and *Eubacterium* compared to *Neisseria*; *Haemophilus*, and *Capnocytophaga*, also suggests a specific dysbiosis signature in SCZ patients. Recently, the oropharyngeal microbiome showed an underrepresentation of *Neisseria Weeksellaceae*, and *Prevotella* in SCZ and individuals with manic episodes (Yolken et al., 2020).

## 12. Substance use disorders

Gut dysbiosis has been reported among subjects with substance use disorders (SUD) and hypotheses have been made regarding whether these differences are consequences of substance use or they contribute to the psychopathology observed among the patients investigated (Meckel and Kiraly, 2019). As such, this section includes both studies of SUD-

affected patients and the effects observed among users of addictive substances. Comparing intestinal microbiota in SUD patients and healthy controls, the species diversity index and the abundance of *Thauera*, *Paracoccus*, and *Prevotella* were increased in SUD individuals with over-representation of microbial pathways related to translation, DNA replication and repair, and cell growth (Xu et al., 2017). Changes in microbiome community composition suggest negative impact of alcohol dependence on gut microbiota (Dubinkina et al., 2017). Alcohol dependent subjects also show altered gut permeability, which is related to higher scores greater acute depression, anxiety, and alcohol craving after abstinence (Leclercq et al., 2014). Gut permeability appears to induce neuroinflammation associated with changes in mood, cognition, and alcohol abuse (Leclercq et al., 2017). Among the gut-derived bacterial products, the permeation of lipopolysaccharides and peptidoglycans was observed to stimulate certain inflammatory pathways in peripheral blood mononuclear cells associated with alcohol craving (Temko et al., 2017; Leclercq et al., 2014). While tobacco smoking generally decreases gut microbiome diversity, it increases the abundance of *Proteobacteria*, *Clostridium*, *Bacteroides*, and *Prevotella* (Savin et al., 2018). Cigarette smoking is also associated with changes in the oral microbiome with differences between active smokers, former smokers, and never smokers. Active smokers show a depletion of *Proteobacteria*, *Capnocytophaga*, and *Peptostreptococcus* and *Leptotrichia* and an enrichment of *Atopobium* and *Streptococcus* (Wu et al., 2016). Smoking-associated changes in oral microbiomes were related to changes in microbial genes associated with carbohydrate, energy, and xenobiotic metabolisms (Wu et al., 2016).

Based on resting-state functional magnetic resonance imaging, changes in brain functional connectivity (mainly including connectivity between brain default network and other task-positive networks) were observed to be associated with microbial imbalance caused by nicotine dependence in smokers (Lin et al., 2019). A consistent association between gut microbiota and opioid-related traits has been reported across multiple studies (Ren and Lotfipour, 2020). Mu-opioid receptors in neurons within the myenteric ganglia or on nerve terminals innervating smooth muscle cells appear to affect analgesic tolerance to opioids (Akbarali and Dewey, 2017). In patients affected by type-2 diabetes, the abundance of *Bifidobacterium* and *Prevotella* genera in the gut microbiome appears to be regulated by the interaction of exogenous opioids with mu-opioid receptors in the gut (Barengolts et al., 2018). In male C57Bl6/J mice treated with intermittent morphine, depletion of the gut microbiota showed increased neuroinflammation, reduced opioid analgesic potency, and impaired cocaine reward (Lee et al., 2018). In mouse models, the bacterial depletion with oral gavage of an antibiotic cocktail reduced gut bacteria and morphine-induced gut permeability, also showing the ability to prevent tolerance while not altering naloxone withdrawal susceptibility (Kang et al., 2017). In a self-directed intake model, a diet enriched for omega-3 polyunsaturated fatty acids increases microbial richness, phylogenetic diversity, and evenness, improving oxycodone-seeking behaviors (Hakimian et al., 2019).

In cannabis users, the abundance of *Prevotella* genera in gut microbiome was positively correlated with fluid cognition which is associated with the capacity of an individual to process information, flanker inhibitory control, working memory, and cognitive flexibility (Panee et al., 2018). These associations were not observed in cannabis non-users.

### 13. Conclusions

The study of the human microbiome in the context of psychiatric disorders is an emerging and promising field of study. To date, most studies are focused on the gut-brain axis and neuroinflammation, highlighting potential pathogenetic mechanisms in the context of psychiatric traits (Clapp et al., 2017; Kim and Shin, 2018). Although there are a limited number of investigations, oral and skin microbiome can also affect mental health (Hadian et al., 2020; Lin et al., 2020; Olsen and

Hicks, 2020). The current state of microbiome research in neuropsychiatry presents several major limitations. There is a general lack of statistical power in human studies due to the limited number of individuals tested (Cheung et al., 2019). Studies conducted examining the association of microbiome variation with psychiatric disorders often fail to account adequately for potential confounding factors, such as diet, age, sex, comorbidities, and their associated medications (Kho and Lal, 2018). Another important limitation that is not limited to neuropsychiatry research is the lack of established standards for microbiome analysis and interpretation that makes difficult to compare findings generated using different analytic frameworks (Morton et al., 2019; Szczyrba et al., 2017). Although the number of associations between microbiome variation and psychiatric disorders is rapidly growing, there is a systematic lack of mechanistic studies to understand the underlying processes by which the human microbiome affects mental health. These should include human, *in vitro*, *in vivo*, and computational approaches focused on understanding the implications of microbiome function in the context of disease and behavior. A better comprehension of the relationship between the human microbiome and mental health will permit the use of many probiotics and prebiotics, which may augment the effects of current treatment approaches for neuropsychiatric disorders. This could particularly benefit a consistent portion of psychiatric patients not responding to current pharmacological therapies.

### Acknowledgements and Declaration of Interest

The authors acknowledge support from the National Institutes of Health (R21 DA047527, R21 DC018098, and F32 MH122058). Dr. Polimanti is paid for his editorial work on the journal Complex Psychiatry. The other authors report no biomedical financial interests or potential conflicts of interest.

### References

- Aarts, E., Ederveen, T.H., Naaijen, J., Zwijs, M.P., Boekhorst, J., Timmerman, H.M., Smeekens, S.P., Netea, M.G., Buitelaar, J.K., Franke, B., 2017. Gut microbiome in ADHD and its relation to neural reward anticipation. *PLoS ONE* 12.
- Adams, J.B., Johansen, L.J., Powell, L.D., Quig, D., Rubin, R.A., 2011. Gastrointestinal flora and gastrointestinal status in children with autism—comparisons to typical children and correlation with autism severity. *BMC Gastroenterol.* 11, 22.
- Akbarali, H.I., Dewey, W.L., 2017. The gut-brain interaction in opioid tolerance. *Curr. Opin. Pharmacol.* 37, 126–130.
- Akbari, E., Asemi, Z., Daneshvar Kakhaki, R., Bahmani, F., Kouchaki, E., Tamtaji, O.R., Hamidi, G.A., Salami, M., 2016. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease: a randomized, double-blind and controlled trial. *Front. Aging Neurosci.* 8, 256.
- Alam, R., Abdolmaleky, H.M., Zhou, J.R., 2017. Microbiome, inflammation, epigenetic alterations, and mental diseases. *Am. J. Med. Genet. Part B: Neuropsychiatric Genet.* 174, 651–660.
- Allswede, D.M., Buka, S.L., Yolken, R.H., Torrey, E.F., Cannon, T.D., 2016. Elevated maternal cytokine levels at birth and risk for psychosis in adult offspring. *Schizophr. Res.* 172, 41–45.
- Altieri, L., Neri, C., Sacco, R., Curatolo, P., Benvenuto, A., Muratori, F., Santocchi, E., Bravaccio, C., Lenti, C., Saccani, M., 2011. Urinary p-cresol is elevated in small children with severe autism spectrum disorder. *Biomarkers* 16, 252–260.
- Arck, P., Handjiski, B., Hagen, E., Pincus, M., Bruenahl, C., Bienenstock, J., Paus, R., 2010. Is there a 'gut-brain-skin axis'? *Exp. Dermatol.* 19, 401–405.
- Armougom, F., Henry, M., Vialettes, B., Raccach, D., Raoult, D., 2009. Monitoring bacterial community of human gut microbiota reveals an increase in *Lactobacillus* in obese patients and *Methanogens* in anorexic patients. *PLoS ONE* 4, e7125.
- Ashton, J.J., Beattie, R.M., Ennis, S., Cleary, D.W., 2016. Analysis and interpretation of the human microbiome. *Inflamm. Bowel Dis.* 22, 1713–1722.
- Barengolts, E., Green, S.J., Eisenberg, Y., Akbar, A., Reddivari, B., Layden, B.T., Dugas, L., Chlipala, G., 2018. Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease. *PLoS ONE* 13, e0194171.
- Bastiaansen, T.F.S., Cusotto, S., Claesson, M.J., Clarke, G., Dinan, T.G., Cryan, J.F., 2020. Gutted! Unraveling the role of the microbiome in major depressive disorder. *Harv. Rev. Psychiatry* 28, 26–39.
- Belkaid, Y., Hand, T.W., 2014. Role of the microbiota in immunity and inflammation. *Cell* 157, 121–141.
- Bellono, N.W., Bayrer, J.R., Leitch, D.B., Castro, J., Zhang, C., O'Donnell, T.A., Brierley, S.M., Ingraham, H.A., Julius, D., 2017. Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. *Cell* 170 185–198, e16.



- Bercik, P., Denou, E., Collins, J., Jackson, W., Lu, J., Jury, J., Deng, Y., Blennerhassett, P., Macri, J., McCoy, K.D., 2011. The intestinal microbiota affect central levels of brain-derived neurotrophic factor and behavior in mice. *Gastroenterology* 141 599–609, e3.
- Bhatt, A.P., Redinbo, M.R., Bultman, S.J., 2017. The role of the microbiome in cancer development and therapy. *CA Cancer J. Clin.* 67, 326–344.
- Blandino, G., Inturri, R., Lazzara, F., Di Rosa, M., Malaguarnera, L., 2016. Impact of gut microbiota on diabetes mellitus. *Diabetes Metab.* 42, 303–315.
- Borgo, F., Riva, A., Benetti, A., Casiraghi, M.C., Bertelli, S., Garbossa, S., Anselmetti, S., Scarone, S., Pontiroli, A.E., Morace, G., Borghi, E., 2017. Microbiota in anorexia nervosa: the triangle between bacterial species, metabolites and psychological tests. *PLoS ONE* 12, e0179739.
- Buffington, S.A., Di Prisco, G.V., Auchtung, T.A., Ajami, N.J., Petrosino, J.F., Costa-Mattoli, M., 2016. Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. *Cell* 165, 1762–1775.
- Bull-Larsen, S., Mohajeri, M.H., 2019. The potential influence of the bacterial microbiome on the development and progression of ADHD. *Nutrients* 11.
- Bull-Larsen, S., Mohajeri, M.H., 2019. The potential influence of the bacterial microbiome on the development and progression of ADHD. *Nutrients* 11, 2805.
- Butler, R.R., Soomer-James, J.T., Frenette, M., Pombert, J.-F., 2017. Complete genome sequences of two human oral microbiome commensals: *Streptococcus salivarius* ATCC 25975 and *S. salivarius* ATCC 27945. *Genome Announc.* 5, e00536–e617.
- Carabotti, M., Scirocco, A., Maselli, M.A., Severi, C., 2015. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. *Ann. Gastroenterol.: Quarterly Publication of the Hellenic Society of Gastroenterology* 28, 203.
- Carter, C., 2011. Schizophrenia: a pathogenetic autoimmune disease caused by viruses and pathogens and dependent on genes. *J. Pathogens*.
- Caspani, G., Kennedy, S., Foster, J.A., Swann, J., 2019. Gut microbial metabolites in depression: understanding the biochemical mechanisms. *Microbial Cell* 6, 454.
- Castro-Nallar, E., Bendall, M.L., Pérez-Losada, M., Sabuncyan, S., Severance, E.G., Dickerson, F.B., Schroeder, J.R., Yolken, R.H., Crandall, K.A., 2015. Composition, taxonomy and functional diversity of the oropharynx microbiome in individuals with schizophrenia and controls. *PeerJ* 3, e1140.
- Chen, L., Li, J., Zhu, W., Kuang, Y., Liu, T., Zhang, W., Chen, X., Peng, C., 2020. Skin and gut microbiome in psoriasis: gaining insight into the pathophysiology of it and finding novel therapeutic strategies. *Front. Microbiol.* 11, 589726.
- Chen, Y.H., Xue, F., Yu, S.F., Li, X.S., Liu, L., Jia, Y.Y., Yan, W.J., Tan, Q.R., Wang, H.N., Peng, Z.W., 2021. Gut microbiota dysbiosis in depressed women: the association of symptom severity and microbiota function. *J. Affect. Disord.* 282, 391–400.
- Chen, T., Yu, W.-H., Izard, J., Baranova, O.V., Lakshmanan, A., Dewhirst, F.E., 2010. The Human Oral Microbiome Database: a web accessible resource for investigating oral microbe taxonomic and genomic information. *Database* 2010.
- Cheung, S.G., Goldenthal, A.R., Uhlemann, A.-C., Mann, J.J., Miller, J.M., Sublette, M.E., 2019. Systematic review of gut microbiota and major depression. *Front. Psychiatry* 10, 34.
- Chunchai, T., Thunapong, W., Yasom, S., Wanchai, K., Eaimworawuthikul, S., Metzler, G., Lungkaphin, A., Pongchaidetcha, A., Sirilun, S., Chaiyasut, C., 2018. Decreased microglial activation through gut-brain axis by prebiotics, probiotics, or synbiotics effectively restored cognitive function in obese-insulin resistant rats. *J. Neuroinflamm.* 15, 11.
- Claessens, M.J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery, E., Marchesi, J.R., Falush, D., Dinan, T., Fitzgerald, G., 2011. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc. Natl. Acad. Sci.* 108, 4586–4591.
- Clapp, M., Aurora, N., Herrera, L., Bhatia, M., Wilen, E., Wakefield, S., 2017. Gut microbiota's effect on mental health: the gut-brain axis. *Clin. Pract.* 7.
- Clarke, G., Grenham, S., Scully, P., Fitzgerald, P., Moloney, R., Shanahan, F., Dinan, T., Cryan, J., 2013. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. *Mol. Psychiatry* 18, 666–673.
- Coello, K., Hansen, T.H., Sørensen, N., Munkholm, K., Kessing, L.V., Pedersen, O., Vinberg, M., 2019. Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. *Brain Behav. Immun.* 75, 112–118.
- Coretti, L., Paparo, L., Riccio, M.P., Amato, F., Cuomo, M., Natale, A., Borrelli, L., Corrado, G., De Caro, C., Cologna, M., 2018. Gut microbiota features in young children with autism spectrum disorders. *Front. Microbiol.* 9, 3146.
- Couereuil, M., Lecuyer, H., Bourdoulous, S., Nassif, X., 2017. A journey into the brain: insight into how bacterial pathogens cross blood–brain barriers. *Nat. Rev. Microbiol.* 15, 149–159.
- Cowan, C.S.M., Dinan, T.G., Cryan, J.F., 2020. Annual Research Review: critical windows – the microbiota-gut-brain axis in neurocognitive development. *J. Child Psychol. Psychiatry* 61, 353–371.
- Cruz-Pereira, J.S., Cryan, J.F., 2020. In need of a quorum: from microbes to mood via the immune system. *Am. J. Psychiatry* 177, 895–897.
- Cruz-Pereira, J.S., Rea, K., Nolan, Y.M., O'Leary, O.F., Dinan, T.G., Cryan, J.F., 2020. Depression's unholy trinity: dysregulated stress, immunity, and the microbiome. *Annu. Rev. Psychol.* 71, 49–78.
- Cryan, J.F., O'Riordan, K.J., Sandhu, K., Peterson, V., Dinan, T.G., 2020. The gut microbiome in neurological disorders. *Lancet Neurol.* 19, 179–194.
- Cummings, J., Macfarlane, G., Macfarlane, S., 2003. Intestinal bacteria and ulcerative colitis. *Curr. Issues Intest. Microbiol.* 4, 9–20.
- Dan, Z., Mao, X., Liu, Q., Guo, M., Zhuang, Y., Liu, Z., Chen, K., Chen, J., Xu, R., Tang, J., 2020. Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder. *Gut Microbes* 1–22.
- De Angelis, M., Francavilla, R., Piccolo, M., De Giacomo, A., Gobbetti, M., 2015. Autism spectrum disorders and intestinal microbiota. *Gut Microbes* 6, 207–213.
- De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchamp, A., Bäckhed, F., Mithieux, G., 2014. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. *Cell* 156, 84–96.
- Del Angel-Meza, A., Dávalos-Marín, A., Ontiveros-Martínez, L., Ortiz, G., Beas-Zarate, C., Chaparro-Huerta, V., Torres-Mendoza, B., Bitzer-Quintero, O., 2011. Protective effects of tryptophan on neuro-inflammation in rats after administering lipopolysaccharide. *Biomed. Pharmacother.* 65, 215–219.
- Dewhirst, F.E., Chen, T., Izard, J., Paster, B.J., Tanner, A.C., Yu, W.-H., Lakshmanan, A., Wade, W.G., 2010. The human oral microbiome. *J. Bacteriol.* 192, 5002–5017.
- Dickerson, F., Severance, E., Yolken, R., 2017. The microbiome, immunity, and schizophrenia and bipolar disorder. *Brain Behav. Immun.* 62, 46–52.
- Dinan, T.G., Cryan, J.F., Stanton, C., 2018. Gut microbes and brain development have black box connectivity. *Biol. Psychiatry* 83, 97–99.
- Ding, H.T., Taur, Y., Walkup, J.T., 2017. Gut microbiota and autism: key concepts and findings. *J. Autism Dev. Disord.* 47, 480–489.
- Dubinkina, V.B., Tyakht, A.V., Odintsova, V.Y., Yarygin, K.S., Kovarsky, B.A., Pavlenko, A.V., Ischenko, D.S., Popenko, A.S., Alexeev, D.G., Taraskina, A.Y., Nasyrova, R.F., Krupitsky, E.M., Shalikiani, N.V., Bakulin, I.G., Shcherbakov, P.L., Skorodumova, L.O., Larin, A.K., Kostyukova, E.S., Abdulkhakov, R.A., Abdulkhakov, S.R., Malanin, S.Y., Ismagilova, R.K., Grigoryeva, T.V., Ilina, E.N., Govorun, V.M., 2017. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. *Microbiome* 5, 141.
- Emery, D.C., Shoemark, D.K., Batstone, T.E., Waterfall, C.M., Coghill, J.A., Cerajewska, T.L., Davies, M., West, N.X., Allen, S.J., 2017. 16S rRNA next generation sequencing analysis shows bacteria in Alzheimer's post-mortem brain. *Front. Aging Neurosci.* 9, 195.
- Evans, S.J., Bassis, C.M., Hein, R., Assari, S., Flowers, S.A., Kelly, M.B., Young, V.B., Ellingrod, V.E., McInnis, M.G., 2017. The gut microbiome composition associates with bipolar disorder and illness severity. *J. Psychiatr. Res.* 87, 23–29.
- Faras, H., Al Ateeqi, N., Tidmarsh, L., 2010. Autism spectrum disorders. *Ann. Saudi Med.* 30, 295–300.
- Fattorusso, A., Di Genova, L., Dell'Isola, G.B., Mencaroni, E., Esposito, S., 2019. Autism spectrum disorders and the gut microbiota. *Nutrients* 11, 521.
- Finegold, S.M., Dowd, S.E., Gontcharova, V., Liu, C., Henley, K.E., Wolcott, R.D., Youn, E., Summanen, P.H., Granpeesheh, D., Dixon, D., Liu, M., Molitoris, D.R., Green 3rd, J.A., 2010. Pyrosequencing study of fecal microflora of autistic and control children. *Anaerobe* 16, 444–453.
- Flowers, S.A., Evans, S.J., Ward, K.M., McInnis, M.G., Ellingrod, V.L., 2017. Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort. *Pharmacother.: J. Human Pharmacol. Drug Therapy* 37, 261–267.
- Forsyth, A., Raslan, K., Lyashenko, C., Bona, S., Snow, M., Khor, B., Herrman, E., Ortiz, S., Choi, D., Maier, T., 2020. Children with autism spectrum disorder: Pilot studies examining the salivary microbiome and implications for gut metabolism and social behavior. *Hum. Microbiome J.* 15, 100066.
- Friedrich, M., 2017. Depression is the leading cause of disability around the world. *JAMA* 317, 1517.
- Gabriele, S., Sacco, R., Cerullo, S., Neri, C., Urbani, A., Tripi, G., Malvy, J., Barthelemy, C., Bonnet-Brihault, F., Persico, A.M., 2014. Urinary p-cresol is elevated in young French children with autism spectrum disorder: a replication study. *Biomarkers* 19, 463–470.
- Galley, J.D., Nelson, M.C., Yu, Z., Dowd, S.E., Walter, J., Kumar, P.S., Lyte, M., Bailey, M. T., 2014. Exposure to a social stressor disrupts the community structure of the colonic mucosa-associated microbiota. *BMC Microbiol.* 14, 189.
- Gaugler, J., James, B., Johnson, T., Marin, A., Weuve, J., 2019. Alzheimer's disease facts and figures. *Alzheimers & Dementia* 15 (2019), 321–387.
- Gevers, D., Knight, R., Petrosino, J.F., Huang, K., McGuire, A.L., Birren, B.W., Nelson, K. E., White, O., Methé, B.A., Huttenhower, C., 2012. The Human Microbiome Project: a community resource for the healthy human microbiome. *PLoS Biol.* 10.
- Gilbert, J.A., Blaser, M.J., Caporaso, J.G., Jansson, J.K., Lynch, S.V., Knight, R., 2018. Current understanding of the human microbiome. *Nat. Med.* 24, 392–400.
- Glassner, K.L., Abraham, B.P., Quigley, E.M., 2020. The microbiome and inflammatory bowel disease. *J. Allergy Clin. Immunol.* 145, 16–27.
- Gondalia, S.V., Palombo, E.A., Knowles, S.R., Austin, D.W., 2010. Faecal microbiota of individuals with autism spectrum disorder. *E-J. Appl. Psychol. Clin. Soc. Issues* 6, 24–29.
- Goowood, P., Blanchet-Collet, C., Chartrel, N., Duclos, J., Dechelotte, P., Hanachi, M., Fetisov, S., Godart, N., Melchior, J.-C., Ramoz, N., 2016. New insights in anorexia nervosa. *Front. Neurosci.* 10, 256.
- Grazul, H., Kanda, L.L., Gondek, D., 2016. Impact of probiotic supplements on microbiome diversity following antibiotic treatment of mice. *Gut Microbes* 7, 101–114.
- Grice, E.A., Segre, J.A., 2011. The skin microbiome. *Nat. Rev. Microbiol.* 9, 244–253.
- Guo, L., Ji, C., Ma, Q., Fan, Y., Feng, J., Chen, C., 2018. The diversity and the abundance of gut microbiome in patients with bipolar disorder. *Chin. J. Psychiatry* 51, 98–104.
- Hadian, Y., Gregoso, D., Nguyen, C., Bagoos, M.D., Dahle, S.E., Gareau, M.G., Isseroff, R. R., 2020. Microbiome-skin-brain axis: a novel paradigm for cutaneous wounds. *Wound Repair Regen.* 28, 282–292.
- Hakimian, J.K., Dong, T.S., Barahona, J.A., Lagishetty, V., Tiwari, S., Azani, D., Barrera, M., Lee, S., Severino, A.L., Mittal, N., Cahill, C.M., Jacobs, J.P., Walwyn, W. M., 2019. Dietary Supplementation with Omega-3 Polyunsaturated Fatty Acids Reduces Opioid-Seeking Behaviors and Alters the Gut Microbiome. *Nutrients* 11.
- Heijtz, R.D., Wang, S., Anuar, F., Qian, Y., Björkholm, B., Samuelsson, A., Hibberd, M.L., Forsberg, H., Pettersson, S., 2011. Normal gut microbiota modulates brain development and behavior. *Proc. Natl. Acad. Sci.* 108, 3047–3052.



- Herpertz-Dahlmann, B., Seitz, J., Baines, J., 2017. Food matters: how the microbiome and gut–brain interaction might impact the development and course of anorexia nervosa. *Eur. Child Adolesc. Psychiatry* 26, 1031–1041.
- Hill, J.M., Clement, C., Pogue, A.I., Bhattacharjee, S., Zhao, Y., Lukiw, W.J., 2014. Pathogenic microbes, the microbiome, and Alzheimer's disease (AD). *Front. Aging Neurosci.* 6, 127.
- Horvath, K., Papadimitriou, J.C., Rabsztyan, A., Drachenberg, C., Tildon, J.T., 1999. Gastrointestinal abnormalities in children with autistic disorder. *J. Pediatrics* 135, 559–563.
- Hoyle, L., Snelling, T., Umlai, U.-K., Nicholson, J.K., Carding, S.R., Glen, R.C., McArthur, S., 2018. Microbiome–host systems interactions: protective effects of propionate upon the blood–brain barrier. *Microbiome* 6, 1–13.
- Hsiao, E.Y., McBride, S.W., Hsien, S., Sharon, G., Hyde, E.R., McCue, T., Codelli, J.A., Chow, J., Reisman, S.E., Petrosino, J.F., 2013. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. *Cell* 155, 1451–1463.
- Huang, T.-T., Lai, J.-B., Du, Y.-L., Xu, Y., Ruan, L.-M., Hu, S.-H., 2019. Current understanding of gut microbiota in mood disorders: an update of human studies. *Front. Genet.* 10.
- Jiang, H., Ling, Z., Zhang, Y., Mao, H., Ma, Z., Yin, Y., Wang, W., Tang, W., Tan, Z., Shi, J., 2015. Altered fecal microbiota composition in patients with major depressive disorder. *Brain Behav. Immun.* 48, 186–194.
- Kahūzna-Czaplińska, J., Błaszczak, S., 2012. The level of arabinitol in autistic children after probiotic therapy. *Nutrition* 28, 124–126.
- Kang, D.W., Adams, J.B., Gregory, A.C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., Pollard, E.L., Roux, S., Sadowsky, M. J., Lipson, K.S., Sullivan, M.B., Caporaso, J.G., Krajmalnik-Brown, R., 2017. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. *Microbiome* 5, 10.
- Kang, M., Mischel, R.A., Bhav, S., Komla, E., Cho, A., Huang, C., Dewey, W.L., Akbarali, H.I., 2017. The effect of gut microbiome on tolerance to morphine mediated antinociception in mice. *Sci. Rep.* 7, 42658.
- Kashyap, P.C., Chia, N., Nelson, H., Segal, E., Elinav, E., 2017. Microbiome at the frontier of personalized medicine. *Mayo Clinic Proceedings*, Elsevier 1855–1864.
- Kelly, J.R., Borre, Y., O'Brien, C., Patterson, E., El Aidy, S., Deane, J., Kennedy, P.J., Beers, S., Scott, K., Moloney, G., 2016. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. *J. Psychiatr. Res.* 82, 109–118.
- Khandaker, G.M., Stochl, J., Zammit, S., Lewis, G., Jones, P.B., 2014. Childhood Epstein-Barr virus infection and subsequent risk of psychotic experiences in adolescence: a population-based prospective serological study. *Schizophr. Res.* 158, 19–24.
- Kho, Z.Y., Lal, S.K., 2018. The human gut microbiome—a potential controller of wellness and disease. *Front. Microbiol.* 9, 1835.
- Kim, Y.-K., Shin, C., 2018. The microbiota-gut-brain axis in neuropsychiatric disorders: pathophysiological mechanisms and novel treatments. *Curr. Neuropharmacol.* 16, 559–573.
- Kitazawa, M., Medeiros, R., LaFerla, F.M., 2012. Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. *Curr. Pharm. Des.* 18, 1131–1147.
- Kleiman, S.C., Watson, H.J., Bulik-Sullivan, E.C., Huh, E.Y., Tarantino, L.M., Bulik, C.M., Carroll, I.M., 2015. The intestinal microbiota in acute anorexia nervosa and during re-nourishment: relationship to depression, anxiety, and eating disorder psychopathology. *Psychosom. Med.* 77, 969–981.
- Kong, X., Liu, J., Cetinbas, M., Sadreyev, R., Koh, M., Huang, H., Adeseye, A., He, P., Zhu, J., Russell, H., 2019. New and preliminary evidence on altered oral and gut microbiota in individuals with autism spectrum disorder (ASD): implications for ASD diagnosis and subtyping based on microbial biomarkers. *Nutrients* 11, 2128.
- Kowalski, K., Mulak, A., 2019. Brain-gut-microbiota axis in Alzheimer's disease. *J. Neurogastroenterol. Motility* 25, 48.
- Kumperscak, H.G., Gricar, A., Ulen, I., Micetic-Turk, D., 2020. A pilot randomized control trial with the probiotic strain *Lactobacillus rhamnosus* GG (LGG) in ADHD: children and adolescents report better health-related quality of life. *Front. Psychiatry* 11.
- Kuntz, T.M., Gilbert, J.A., 2017. Introducing the microbiome into precision medicine. *Trends Pharmacol. Sci.* 38, 81–91.
- Lach, G., Schellekens, H., Dinan, T.G., Cryan, J.F., 2018. Anxiety, depression, and the microbiome: a role for gut peptides. *Neurotherapeutics* 15, 36–59.
- Lasheras, I., Seral, P., Latorre, E., Barroso, E., Gracia-García, P., Santabàrbara, J., 2020. Microbiota and gut-brain axis dysfunction in autism spectrum disorder: evidence for functional gastrointestinal disorders. *Asian J. Psychiatry* 47, 101874.
- Leblhuber, F., Steiner, K., Schuetz, B., Fuchs, D., Gostner, J.M., 2018. Probiotic supplementation in patients with Alzheimer's dementia—an explorative intervention study. *Curr. Alzheimer Res.* 15, 1106–1113.
- Leclercq, S., De Saeger, C., Delzenne, N., de Timary, P., Stärkel, P., 2014. Role of inflammatory pathways, blood mononuclear cells, and gut-derived bacterial products in alcohol dependence. *Biol. Psychiatry* 76, 725–733.
- Leclercq, S., Matamoros, S., Cani, P.D., Neyrinck, A.M., Jamar, F., Stärkel, P., Windey, K., Tremaroli, V., Bäckhed, F., Verbeke, K., de Timary, P., Delzenne, N.M., 2014. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. *Proc. Natl. Acad. Sci. U S A* 111, E4485–E4493.
- Leclercq, S., de Timary, P., Delzenne, N.M., Stärkel, P., 2017. The link between inflammation, bugs, the intestine and the brain in alcohol dependence. *Transl. Psychiatry* 7, e1048.
- Lee, S.-Y., Lee, E., Park, Y.M., Hong, S.-J., 2018. Microbiome in the gut-skin axis in atopic dermatitis. *Allergy, Asthma Immunol. Res.* 10, 354–362.
- Lee, K., Vuong, H.E., Nusbaum, D.J., Hsiao, E.Y., Evans, C.J., Taylor, A.M.W., 2018. The gut microbiota mediates reward and sensory responses associated with regimen-selective morphine dependence. *Neuropsychopharmacology* 43, 2606–2614.
- Lin, J., Chang, C., Caffrey, J., 2020. Examining the association between oral health status and dementia: a nationwide nested case-controlled study. *Exp. Biol. Med.* 245, 231–244.
- Lin, D., Hutchison, K.E., Portillo, S., Vegara, V., Ellingson, J.M., Liu, J., Krauter, K.S., Carroll-Portillo, A., Calhoun, V.D., 2019. Association between the oral microbiome and brain resting state connectivity in smokers. *Neuroimage* 200, 121–131.
- Liu, R.T., 2017. The microbiome as a novel paradigm in studying stress and mental health. *Am. Psychol.* 72, 655.
- Liu, F., Li, J., Wu, F., Zheng, H., Peng, Q., Zhou, H., 2019. Altered composition and function of intestinal microbiota in autism spectrum disorders: a systematic review. *Transl. Psychiatry* 9, 1–13.
- Lloyd-Price, J., Abu-Ali, G., Huttenhower, C., 2016. The healthy human microbiome. *Genome Med.* 8, 1–11.
- Logan, A.C., Jacka, F.N., Craig, J.M., Prescott, S.L., 2016. The microbiome and mental health: looking back, moving forward with lessons from allergic diseases. *Clin. Psychopharmacol. Neurosci.* 14, 131.
- Long-Smith, C., O'Riordan, K.J., Clarke, G., Stanton, C., Dinan, T.G., Cryan, J.F., 2020. Microbiota-gut-brain axis: new therapeutic opportunities. *Annu. Rev. Pharmacol. Toxicol.* 60, 477–502.
- Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Jansson, J.K., Knight, R., 2012. Diversity, stability and resilience of the human gut microbiota. *Nature* 489, 220–230.
- MacFabe, D.F., 2012. Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. *Microbiol. Health Dis.* 23, 19260.
- Mack, I., Penders, J., Cook, J., Dugmore, J., Mazurak, N., Enck, P., 2018. Is the impact of starvation on the gut microbiota specific or unspecific to anorexia nervosa? A narrative review based on a systematic literature search. *Curr. Neuropharmacol.* 16, 1131–1149.
- Maeda, Y., Takeda, K., 2017. Role of gut microbiota in rheumatoid arthritis. *J. Clin. Med.* 6, 60.
- Maqsood, R., Stone, T.W., 2016. The gut-brain axis, BDNF, NMDA and CNS disorders. *Neurochem. Res.* 41, 2819–2835.
- Margolis, K.G., Cryan, J.F., Mayer, E.A., 2021. The microbiota-gut-brain axis: from motility to mood. *Gastroenterology*.
- Martin, C.R., Osadchiv, V., Kalani, A., Mayer, E.A., 2018. The brain-gut-microbiome axis. *Cell Mol. Gastroenterol. Hepatol.* 6, 133–148.
- Marx, W., Lane, M., Hockey, M., Aslam, H., Berk, M., Walder, K., Borsini, A., Firth, J., Pariante, C.M., Berding, K., Cryan, J.F., Clarke, G., Craig, J.M., Su, K.P., Mischoulon, D., Gomez-Pinilla, F., Foster, J.A., Cani, P.D., Thuret, S., Staudacher, H. M., Sanchez-Villegas, A., Arshad, H., Akbarali, T., O'Neill, A., Segasby, T., Jacka, F. N., 2021. Diet and depression: exploring the biological mechanisms of action. *Mol. Psychiatry* 26, 134–150.
- Masters, C., Bateman, R., Blennow, K., Rowe, C., Sperling, R.A., Cummings, J.L., 2015. Alzheimer's disease. *Nat. Rev. Dis. Primers* 1, 561.
- Matson, J.L., Goldin, R.L., 2014. Diagnosing young children with autism. *Int. J. Dev. Neurosci.* 39, 44–48.
- Mattila, T., Koeter, M., Wohlfarth, T., Storosum, J., van den Brink, W., de Haan, L., Derks, E., Leufkens, H., Denys, D., 2015. Impact of DSM-5 changes on the diagnosis and acute treatment of schizophrenia. *Schizophr. Bull.* 41, 637–643.
- Maydych, V., 2019. The interplay between stress, inflammation, and emotional attention: relevance for depression. *Front. Neurosci.* 13, 384.
- Meckel, K.R., Kiraly, D.D., 2019. A potential role for the gut microbiome in substance use disorders. *Psychopharmacology* 236, 1513–1530.
- Meyer, U., 2014. Prenatal poly (i: C) exposure and other developmental immune activation models in rodent systems. *Biol. Psychiatry* 75, 307–315.
- Minakova, E., Warner, B.B., 2018. Maternal immune activation, central nervous system development and behavioral phenotypes. *Birth Defects Res* 110, 1539–1550.
- Ming, X., Chen, N., Ray, C., Brewer, G., Kornitzer, J., Steer, R.A., 2018. A gut feeling: a hypothesis of the role of the microbiome in attention-deficit/hyperactivity disorders. *Child Neurol. Open* 5, 2329048X18786799.
- Minter, M.R., Zhang, C., Leone, V., Ringus, D.L., Zhang, X., Oyler-Castrillo, P., Musch, M. W., Liao, F., Ward, J.F., Holtzman, D.M., 2016. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. *Sci. Rep.* 6, 30028.
- Mir, R., Jallu, S., Singh, T.P., 2015. The shikimate pathway: review of amino acid sequence, function and three-dimensional structures of the enzymes. *Crit. Rev. Microbiol.* 41, 172–189.
- Mitchell, A.J., 2009. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. *J. Psychiatr. Res.* 43, 411–431.
- Moayyedi, P., Yuan, Y., Baharir, H., Ford, A.C., 2017. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. *Med. J. Aust.* 207, 166–172.
- Mohamadkhani, A., 2018. Gut microbiota and fecal metabolome perturbation in children with autism spectrum disorder. *Middle East J. Digestive Dis.* 10, 205.
- Morita, C., Tsuji, H., Hata, T., Gondo, M., Takakura, S., Kawai, K., Yoshihara, K., Ogata, K., Nomoto, K., Miyazaki, K., Sudo, N., 2015. Gut dysbiosis in patients with anorexia nervosa. *PLoS ONE* 10, e0145274.
- Morita, C., Tsuji, H., Hata, T., Gondo, M., Takakura, S., Kawai, K., Yoshihara, K., Ogata, K., Nomoto, K., Miyazaki, K., 2015. Gut dysbiosis in patients with anorexia nervosa. *PLoS ONE* 10, e0145274.

- Morton, J.T., Marotz, C., Washburne, A., Silverman, J., Zaramela, L.S., Edlund, A., Zengler, K., Knight, R., 2019. Establishing microbial composition measurement standards with reference frames. *Nat. Commun.* 10, 2719.
- Müller-Oerlinghausen, B., Berghöfer, A., Bauer, M., 2002. Bipolar disorder. *The Lancet* 359, 241–247.
- Murphy, K., Edelstein, H., Smith, L., Clanton, K., Schweitzer, B., Reynolds, L., Wheeler, P., 2011. Treatment of HIV in outpatients with schizophrenia, schizoaffective disorder and bipolar disease at two county clinics. *Community Ment. Health J.* 47, 668–671.
- Nagpal, R., Mainali, R., Ahmadi, S., Wang, S., Singh, R., Kavanagh, K., Kitzman, D.W., Kushugulova, A., Marotta, F., Yadav, H., 2018. Gut microbiome and aging: physiological and mechanistic insights. *Nutr. Healthy Aging* 4, 267–285.
- Nagpal, R., Neth, B.J., Wang, S., Mishra, S.P., Craft, S., Yadav, H., 2020. Gut mycobiome and its interaction with diet, gut bacteria and alzheimer's disease markers in subjects with mild cognitive impairment: a pilot study. *EBioMedicine* 59.
- Naseribafrouei, A., Hestad, K., Avershina, E., Sekelja, M., Linlokken, A., Wilson, R., Rudi, K., 2014. Correlation between the human fecal microbiota and depression. *Neurogastroenterol. Motil.* 26, 1155–1162.
- O'Mahony, S.M., Clarke, G., Borre, Y., Dinan, T., Cryan, J., 2015. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. *Behav. Brain Res.* 277, 32–48.
- Oh, J., Byrd, A.L., Park, M., Kong, H.H., Segre, J.A., Program, N.C.S., 2016. Temporal stability of the human skin microbiome. *Cell* 165, 854–866.
- Olsen, I., Hicks, S.D., 2020. Oral microbiota and autism spectrum disorder (ASD). *J. Oral Microbiol.* 12, 1702806.
- O'Neill, C.A., Monteleone, G., McLaughlin, J.T., Paus, R., 2016. The gut-skin axis in health and disease: A paradigm with therapeutic implications. *BioEssays* 38, 1167–1176.
- Paley, E.L., 2019. Diet-related metabolic perturbations of gut microbial shikimate pathway-tryptamine-tRNA aminoacylation-protein synthesis in human health and disease. *Int. J. Tryptophan Res.* 12, 1178646919834550.
- Panee, J., Gerschenson, M., Chang, L., 2018. Associations between microbiota, mitochondrial function, and cognition in chronic marijuana users. *J. Neuroimmune Pharmacol.* 13, 113–122.
- Parracho, H.M., Gibson, G.R., Knott, F., Bosscher, D., Kleerebezem, M., McCartney, A.L., 2010. A double-blind, placebo-controlled, crossover-designed probiotic feeding study in children diagnosed with autistic spectrum disorders. *Int. J. Probiot. Prebiot.* 5, 69.
- Pearson-Leary, J., Zhao, C., Bittinger, K., Eacret, D., Luz, S., Vigderman, A.S., Dayanin, G., Bhatnagar, S., 2020. The gut microbiome regulates the increases in depressive-type behaviors and in inflammatory processes in the ventral hippocampus of stress vulnerable rats. *Mol. Psychiatry* 25, 1068–1079.
- Peirce, J.M., Alviña, K., 2019. The role of inflammation and the gut microbiome in depression and anxiety. *J. Neurosci. Res.* 97, 1223–1241.
- Petra, A.L., Panagiotidou, S., Hatziagelaki, E., Stewart, J.M., Conti, P., Theoharides, T.C., 2015. Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. *Clin. Ther.* 37, 984–995.
- Petschow, B., Doré, J., Hibberd, P., Dinan, T., Reid, G., Blaser, M., Cani, P.D., Degnan, F. H., Foster, J., Gibson, G., 2013. Probiotics, prebiotics, and the host microbiome: the science of translation. *Ann. N. Y. Acad. Sci.* 1306, 1.
- Prieto, G.A., Cotman, C.W., 2017. Cytokines and cytokine networks target neurons to modulate long-term potentiation. *Cytokine Growth Factor Rev.* 34, 27–33.
- Rea, K., Dinan, T.G., Cryan, J.F., 2016. The microbiome: a key regulator of stress and neuroinflammation. *Neurobiol. Stress* 4, 23–33.
- Reininghaus, E.Z., Wetzlmair, L.-C., Fellendorf, F.T., Platzer, M., Queissner, R., Birner, A., Pilz, R., Hamm, C., Maget, A., Koidl, C., 2020. The impact of probiotic supplements on cognitive parameters in euthymic individuals with bipolar disorder: a pilot study. *Neuropsychobiology* 79, 63–70.
- Ren, M., Lotfipour, S., 2020. The role of the gut microbiome in opioid use. *Behav. Pharmacol.* 31, 113–121.
- Rogers, G., Keating, D., Young, R., Wong, M., Licinio, J., Wesselingh, S., 2016. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. *Mol. Psychiatry* 21, 738–748.
- Roman, P., Rueda-Ruzafa, L., Cardona, D., Cortes-Rodríguez, A., 2018. Gut-brain axis in the executive function of autism spectrum disorder. *Behav. Pharmacol.* 29, 654–663.
- Roubalová, R., Procházková, P., Papežová, H., Smitka, K., Bilej, M., Tlaskalová-Hogenová, H., 2020. Anorexia nervosa: Gut microbiota-immune-brain interactions. *Clin. Nutr.* 39, 676–684.
- Ruusunen, A., Rocks, T., Jacka, F., Loughman, A., 2019. The gut microbiome in anorexia nervosa: relevance for nutritional rehabilitation. *Psychopharmacology* 1–14.
- Salem, I., Ramser, A., Isham, N., Ghannoum, M.A., 2018. The gut microbiome as a major regulator of the gut-skin axis. *Front. Microbiol.* 9, 1459.
- Sandler, R.H., Finegold, S.M., Bolte, E.R., Buchanan, C.P., Maxwell, A.P., Väisänen, M.-L., Nelson, M.N., Wexler, H.M., 2000. Short-term benefit from oral vancomycin treatment of regressive-onset autism. *J. Child Neurol.* 15, 429–435.
- Savin, Z., Kivity, S., Yonath, H., Yehuda, S., 2018. Smoking and the intestinal microbiome. *Arch. Microbiol.* 200, 677–684.
- Scharschmidt, T.C., Fischbach, M.A., 2013. What lives on our skin: ecology, genomics and therapeutic opportunities of the skin microbiome. *Drug Discovery Today: Dis. Mech.* 10, e83–e89.
- Schulze-Schweifing, K., Banerjee, A., Wade, W.G., 2014. Comparison of bacterial culture and 16S rRNA community profiling by clonal analysis and pyrosequencing for the characterization of the dentine caries-associated microbiome. *Front. Cell. Infect. Microbiol.* 4, 164.
- Schwartz, D.D., Katzenstein, J.M., Highley, E.J., Stabley, D.L., Sol-Church, K., Gripp, K. W., Axelrad, M.E., 2017. Age-related differences in prevalence of autism spectrum disorder symptoms in children and adolescents with Costello syndrome. *Am. J. Med. Genet. Part A* 173, 1294–1300.
- Schwarz, E., Maukonen, J., Hyttiäinen, T., Kieseppä, T., Orešić, M., Sabunciyani, S., Mantere, O., Saarela, M., Yolken, R., Suvisaari, J., 2018. Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response. *Schizophr. Res.* 192, 398–403.
- Sczyrba, A., Hofmann, P., Belmann, P., Koslicki, D., Janssen, S., Droge, J., Gregor, I., Majda, S., Fiedler, J., Dahms, E., Bremges, A., Fritz, A., Garrido-Oter, R., Jorgensen, T.S., Shapiro, N., Blood, P.D., Gurevich, A., Bai, Y., Turae, D., DeMaere, M.Z., Chikhi, R., Nagarajan, N., Quince, C., Meyer, F., Balvociute, M., Hansen, L.H., Sorensen, S.J., Chia, B.K.H., Denis, B., Froula, J.L., Wang, Z., Egan, R., Don Kang, D., Cook, J.J., Deltel, C., Beckstette, M., Lemaitre, C., Peterlongo, P., Rizk, G., Lavenier, D., Wu, Y.W., Singer, S.W., Jain, C., Strous, M., Klingenberg, H., Meinicke, P., Barton, M.D., Lingner, T., Lin, H.H., Liao, Y.C., Silva, G.G.Z., Cuevas, D. A., Edwards, R.A., Saha, S., Piro, V.C., Renard, B.Y., Pop, M., Klenk, H.P., Goker, M., Kyripides, N.C., Woyke, T., Vorholt, J.A., Schulze-Lefert, P., Rubin, E.M., Darling, A. E., Rattei, T., McHardy, A.C., 2017. Critical Assessment of Metagenome Interpretation—a benchmark of metagenomics software. *Nat. Methods* 14, 1063–1071.
- Seitz, J., Trinh, S., Herpertz-Dahlmann, B., 2019. The microbiome and eating disorders. *Psychiatric Clinics* 42, 93–103.
- Seitz, J., Belheouane, M., Schulz, N., Dempfle, A., Baines, J.F., Herpertz-Dahlmann, B., 2019. The impact of starvation on the microbiome and gut-brain interaction in anorexia nervosa. *Front. Endocrinol.* 10, 41.
- Severance, E.G., Yolken, R.H., 2019. From infection to the microbiome: An evolving role of microbes in schizophrenia. In: *Neuroinflammation and Schizophrenia*. Springer, pp. 67–84.
- Severance, E.G., Gressitt, K.L., Buka, S.L., Cannon, T.D., Yolken, R.H., 2014. Maternal complement C1q and increased odds for psychosis in adult offspring. *Schizophr. Res.* 159, 14–19.
- Severance, E.G., Gressitt, K.L., Stallings, C.R., Katsafanas, E., Schweinfurth, L.A., Savage, C.L., Adamos, M.B., Sweeney, K.M., Origeni, A.E., Khushalani, S., 2017. Probiotic normalization of *Candida albicans* in schizophrenia: a randomized, placebo-controlled, longitudinal pilot study. *Brain Behav. Immun.* 62, 41–45.
- Severance, E.G., Yolken, R.H., 2020. Deciphering microbiome and neuroactive immune gene interactions in schizophrenia. *Neurobiol. Dis.* 135, 104331.
- Silva, Y.P., Bernardi, A., Frozza, R.L., 2020. The role of short-chain fatty acids from gut microbiota in gut-brain communication. *Front. Endocrinol.* 11, 25.
- Sivamaruthi, B.S., Suganthi, N., Kesika, P., Chaiyasut, C., 2020. The role of microbiome, dietary supplements, and probiotics in autism spectrum disorder. *Int. J. Environ. Res. Public Health* 17.
- Solomon, C.G., Mitchell, James E., Peterson, Carol B., 2020. *N. Engl. J. Med.* 382, 1343–1351.
- Sudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X.N., Kubo, C., Koga, Y., 2004. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. *J. Physiol.* 558, 263–275.
- Szopinska-Tokov, J., Dam, S., Naaijen, J., Konstanti, P., Rommelse, N., Belzer, C., Buitelaar, J., Franke, B., Aarts, E., Arias Vasquez, A., 2020. Investigating the gut microbiota composition of individuals with attention-deficit/hyperactivity disorder and association with symptoms. *Microorganisms* 8, 406.
- Tang, W.W., Hazen, S.L., 2014. The contributory role of gut microbiota in cardiovascular disease. *J. Clin. Investig.* 124, 4204–4211.
- Temko, J.E., Bouhhal, S., Farokhnia, M., Lee, M.R., Cryan, J.F., Leggio, L., 2017. The microbiota, the gut and the brain in eating and alcohol use disorders: a 'Ménage à Trois'? *Alcohol Alcohol.* 52, 403–413.
- Tomova, A., Husarova, V., Lakatosova, S., Bakos, J., Vlkova, B., Babinska, K., Ostatnikova, D., 2015. Gastrointestinal microbiota in children with autism in Slovakia. *Physiol. Behav.* 138, 179–187.
- Turner-Cobb, J.M., Osborn, M., da Silva, L., Keogh, E., Jessop, D.S., 2010. Sex differences in hypothalamic-pituitary-adrenal axis function in patients with chronic pain syndrome. *Stress* 13, 293–301.
- Valles-Colomer, M., Falony, G., Darzi, Y., Tigheelaar, E.F., Wang, J., Tito, R.Y., Schiweck, C., Kurilshikov, A., Joossens, M., Wijnenga, C., 2019. The neuroactive potential of the human gut microbiota in quality of life and depression. *Nat. Microbiol.* 4, 623–632.
- Vemuri, R., Sylvia, K.E., Klein, S.L., Forster, S.C., Plebanski, M., Eri, R., Flanagan, K.L., 2019. The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. In: *Seminars in Immunopathology*. Springer, pp. 265–275.
- Wade, W.G., 2013. The oral microbiome in health and disease. *Pharmacol. Res.* 69, 137–143.
- Wallace, C.J., Milev, R., 2017. The effects of probiotics on depressive symptoms in humans: a systematic review. *Ann. General Psychiatry* 16, 14.
- Wan, L., Ge, W.R., Zhang, S., Sun, Y.L., Wang, B., Yang, G., 2020. Case-control study of the effects of gut microbiota composition on neurotransmitter metabolic pathways in children with attention deficit hyperactivity disorder. *Front. Neurosci.* 14, 127.
- Wang, X., Li, Y., Wu, L., Xiao, S., Ji, Y., Tan, Y., Jiang, C., Zhang, G., 2021. Dysregulation of the gut-brain-skin axis and key overlapping inflammatory and immune mechanisms of psoriasis and depression. *Biomed. Pharmacother.* 137, 111065.
- Wu, J., Peters, B.A., Dominiani, C., Zhang, Y., Pei, Z., Yang, L., Ma, Y., Purdue, M.P., Jacobs, E.J., Gapstur, S.M., Li, H., Alekseyenko, A.V., Hayes, R.B., Ahn, J., 2016. Cigarette smoking and the oral microbiome in a large study of American adults. *ISME J.* 10, 2435–2446.
- Xiao, H., Banks, W., Niehoff, M.L., Morley, J., 2001. Effect of LPS on the permeability of the blood-brain barrier to insulin. *Brain Res.* 896, 36–42.

- Xiong, X., Liu, D., Wang, Y., Zeng, T., Peng, Y., 2016. Urinary 3-(3-hydroxyphenyl)-3-hydroxypropionic acid, 3-hydroxyphenylacetic acid, and 3-hydroxyhippuric acid are elevated in children with autism spectrum disorders. *Biomed Res. Int.* 2016.
- Xu, Y., Xie, Z., Wang, H., Shen, Z., Guo, Y., Gao, Y., Chen, X., Wu, Q., Li, X., Wang, K., 2017. Bacterial diversity of intestinal microbiota in patients with substance use disorders revealed by 16S rRNA gene deep sequencing. *Sci. Rep.* 7, 3628.
- Yolken, R., Prandovszky, E., Severance, E.G., Hatfield, G., Dickerson, F., 2020. The oropharyngeal microbiome is altered in individuals with schizophrenia and mania. *Schizophr. Res.*
- Yolken, R.H., Severance, E.G., Sabunciyar, S., Gressitt, K.L., Chen, O., Stallings, C., Origoni, A., Katsafanas, E., Schweinfurth, L.A., Savage, C.L., 2015. Metagenomic sequencing indicates that the oropharyngeal phageome of individuals with schizophrenia differs from that of controls. *Schizophr. Bull.* 41, 1153–1161.
- Yong, S.J., Tong, T., Chew, J., Lim, W.L., 2020. Antidepressive mechanisms of probiotics and their therapeutic potential. *Front. Neurosci.* 13, 1361.
- Zevin, A.S., McKinnon, L., Burgener, A., Klatt, N.R., 2016. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. *Curr. Opin. HIV AIDS* 11, 182.
- Zhang, M., Ma, W., Zhang, J., He, Y., Wang, J., 2018. Analysis of gut microbiota profiles and microbe-disease associations in children with autism spectrum disorders in China. *Sci. Rep.* 8, 13981.
- Zhao, Y., Cong, L., Jaber, V., Lukiw, W.J., 2017. Microbiome-derived lipopolysaccharide enriched in the perinuclear region of Alzheimer's disease brain. *Front. Immunol.* 8, 1064.
- Zheng, H.-Z., Tu, J.-L., Li, X.-H., Hua, Q., Liu, W.-Z., Liu, Y., Pan, B.-X., Hu, P., Zhang, W.-H., 2020. Neuroinflammation induces anxiety-and depressive-like behavior by modulating neuronal plasticity in the basolateral amygdala. *Brain Behav. Immun.*
- Zheng, P., Zeng, B., Zhou, C., Liu, M., Fang, Z., Xu, X., Zeng, L., Chen, J., Fan, S., Du, X., 2016. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. *Mol. Psychiatry* 21, 786–796.
- Zhu, B., Wang, Z.G., Ding, J., Liu, N., Wang, D.M., Ding, L.C., Yang, C., 2014. Chronic lipopolysaccharide exposure induces cognitive dysfunction without affecting BDNF expression in the rat hippocampus. *Exp. Therap. Med.* 7, 750–754.
- Zmora, N., Zeevi, D., Korem, T., Segal, E., Elinav, E., 2016. Taking it personally: personalized utilization of the human microbiome in health and disease. *Cell Host Microbe* 19, 12–20.